Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Glyceryl trinitrate
Ayrton Saunders (Ireland) Limited
C01DA; C01DA02
Glyceryl trinitrate
0.7%w/w percent weight/weight
Sublingual spray, solution
Organic nitrates; glyceryl trinitrate
Not marketed
1990-11-29
PACKAGE LEAFLET: INFORMATION FOR THE USER GLYTRIN 400 MICROGRAMS PER METERED DOSE, SUBLINGUAL SPRAY glyceryl trinitrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Glytrin is and what it is used for 2. What you need to know before you use Glytrin 3. How to use Glytrin 4. Possible side effects 5. How to store Glytrin 6. Contents of the pack and other information 1. WHAT GLYTRIN IS AND WHAT IT IS USED FOR Your medicine is called Glytrin. It is a sublingual (under the tongue) aerosol spray that contains the active ingredient glyceryl trinitrate. Glyceryl trinitrate belongs to a group of medicines called nitrates that relax the muscle walls of the blood vessels and reduce the workload of the heart. Glytrin is used to treat angina at the onset of an attack. It is also used for the prevention of angina, which can be brought on from physical effort, emotional stress, exposure to cold, etc. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE GLYTRIN DO NOT USE GLYTRIN AND TALK TO YOUR DOCTOR IF YOU: • Are ALLERGIC to glyceryl trinitrate or any of the other ingredients of this medicine (listed in section 6). • Have severe LOW BLOOD PRESSURE. • Have SHOCK caused by low blood pressure. • Have severe ANAEMIA. • Have CONSTRICTIVE PERICARDITIS (a heart condition). • Have an extremely LOW HEART RATE. • Have a BRAIN TRAUMA OR CEREBRAL HAEMORRHAGE (brain or head injury, including bleeding). • Have NARROWING OF THE HEART VALVES OR ARTERIES or angina caused by a disease of the heart muscle. • Hav Read the complete document
Health Products Regulatory Authority 02 June 2023 CRN00DHZR Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Glytrin 400 micrograms per metered dose Sublingual Spray 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose delivers 8.8 mg of solution containing 400 micrograms of glyceryl trinitrate Excipient(s) with known effect Ethanol (alcohol) – 7.5 mg per metered dose For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Sublingual spray, solution Pressurised metered dose aerosol canister containing a colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of acute angina pectoris. Prevention of inducible angina (e.g. physical effort, emotional stress, exposure to cold). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Sublingual Dosage _Adults including the Elderly_ At the onset of an attack: one or two metered sprays (400 to 800 micrograms glyceryl trinitrate) to be sprayed under the tongue for the relief of anginal pain while the breath is held. If symptoms do not resolve, this may be repeated at five-minute intervals for a total of three sprays (maximum of 1.2mg taken within 15 minutes). If symptoms have not resolved after a total of three sprays, immediate medical attention should be sought. For the prevention of inducible angina (e.g. due to physical effort, emotional stress, exposure to cold) one or two metered sprays (400 to 800 micrograms glyceryl trinitrate) to be sprayed under the tongue 2 to 3 minutes prior to activity likely to cause angina. _Paediatric population_ Glytrin should not be used in children and adolescents under 18 years. Method of administration During application the patient should rest, ideally in the sitting position. The canister should be held vertically with the valve head uppermost and the spray orifice as close to the mouth as possible. The dose should be sprayed under the tongue and the mouth should be closed immediately after each dose. The spray should not be inhaled. Patients should be inst Read the complete document